XML 27 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Revenues
 9 Months Ended
Sep. 30, 2021
Revenue from Contract with Customer [Abstract]  
Revenues

6. Revenues

Revenues by product line. The following table represents total net revenues by product line:

 

 

 

Three Months Ended September 30,

Nine Months Ended September 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

Infectious disease testing

 

$

12,932

 

 

$

13,224

 

 

$

39,664

 

 

$

36,625

 

 

Risk assessment testing

 

 

2,674

 

 

 

2,253

 

 

 

7,265

 

 

 

6,786

 

 

Genomics (1)

 

 

19,018

 

 

 

8,454

 

 

 

49,333

 

 

 

23,224

 

 

Microbiome (1)

 

 

1,693

 

 

 

1,530

 

 

 

5,888

 

 

 

3,869

 

 

COVID-19 (1)

 

 

13,930

 

 

 

18,867

 

 

 

54,147

 

 

 

27,918

 

 

Laboratory services

 

 

2,406

 

 

 

2,280

 

 

 

8,017

 

 

 

6,798

 

 

Other product and service revenues

 

 

576

 

 

 

141

 

 

 

1,235

 

 

 

752

 

 

Net product and services revenues

 

 

53,229

 

 

 

46,749

 

 

 

165,549

 

 

 

105,972

 

 

Royalty income

 

 

500

 

 

 

450

 

 

 

2,636

 

 

 

1,623

 

 

Other non-product revenues

 

 

188

 

 

 

812

 

 

 

1,921

 

 

 

1,271

 

 

Other revenues

 

 

688

 

 

 

1,262

 

 

 

4,557

 

 

 

2,894

 

 

Net revenues

 

$

53,917

 

 

$

48,011

 

 

$

170,106

 

 

$

108,866

 

 

 

 

(1) 2020 Genomics, Microbiome, and COVID-19 revenues were reclassified to reflect the correct classification of the product line sales. The reclassification increased (decreased) the product line revenues for the three months ended September 30, 2020 by $(65), $(298), and $363, respectively and increased (decreased) the product line revenue for the nine months ended September 30, 2020 by $(157), $(390), and $547, respectively.

 

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

 

 

 

Three Months Ended September 30,

 

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

 

2021

 

 

2020

 

United States

 

$

42,969

 

 

$

38,594

 

 

 

$

139,669

 

 

$

82,125

 

Europe

 

 

2,411

 

 

 

2,789

 

 

 

 

10,288

 

 

 

8,663

 

Other regions

 

 

8,537

 

 

 

6,628

 

 

 

 

20,149

 

 

 

18,078

 

 

 

$

53,917

 

 

$

48,011

 

 

 

$

170,106

 

 

$

108,866

 

 

Customer and Vendor Concentrations. At September 30, 2021, one customer accounted for 13% of our accounts receivable. Another customer accounted for 11% of our accounts receivable as of December 31, 2020. One customer accounted for 14% of net consolidated revenues for the three months ended September 30, 2021. Another customer accounted for 10% of net consolidated revenues for the nine months ended September 30, 2021. One customer accounted for 11% of net consolidated revenues for the three months ended September 30, 2020.

 

We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Third-party suppliers also manufacture certain products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

 

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of September 30, 2021 and December 31, 2020 includes customer prepayments of $2,340 and $3,216, respectively. Deferred revenue as of September 30, 2021 and December 31, 2020 also includes $1,148 and $1,595, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue is recognized at that average price.